Asterias Biotherapeutics Inc. (AST) 14.77 $AST
What's New in the Pharma Sector: Free Research on Asterias, Dicerna,OncoMed, Heron, and Providence Service Corporation
PR Newswire - Thu Apr 23, 7:20AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PRSC: 49.35 (+0.02), HRTX: 14.18 (-0.06), DRNA: 24.18 (-0.25), OMED: 26.16 (+0.29), AST: 14.77 (+0.66)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 11:47AM CDT
RNO: 2.09 (+0.13), ECHO: 32.68 (-1.14), LJPC: 22.95 (-1.39), CEA: 40.74 (-2.76), NVGN: 6.54 (-0.01), NHLD: 3.78 (-0.18), VLTC: 11.54 (+0.50), GEVO: 2.72 (-0.10), BIOD: 1.14 (-0.13), PRTO: 12.30 (+0.01), TTS: 14.01 (-0.17), ENZN: 1.72 (+0.18), AST: 14.77 (+0.66), VGGL: 2.55 (-0.10), GLF: 13.58 (-0.05), NVTA: 13.23 (+0.41), FTK: 14.06 (-0.43), PGN: 1.69 (unch), UCTT: 6.26 (+0.60), SANM: 20.81 (-0.03)
Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting
PR Newswire - Tue Apr 21, 6:00AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that the abstract describing long-term follow-up of patients with acute myelogenous leukemia (AML) from the Phase 2 clinical trial of the Company's autologous telomerase-based dendritic cell cancer vaccine, AST-VAC1, has been selected for an oral presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago, Illinois May 29 - June 2, 2015.
AST: 14.77 (+0.66)
AusNet Services Selects Silver Spring Networks for Advanced Metering Roll-Out
Business Wire - Thu Apr 16, 7:30AM CDT
Silver Spring Networks (NYSE:SSNI) today announced its selection by AusNet Services (ASX:AST), the state of Victoria's largest diversified energy network business, to support its roll-out of the Victorian government's mandated Advanced Metering Infrastructure (AMI) program. Silver Spring will deploy and support the initial operations of a multi-application, IPv6 network canopy as an infill solution within AusNet Services' territory across Eastern Victoria. The Silver Spring solution will complement AusNet Services' existing core technology systems.
AST: 14.77 (+0.66), SSNI: 10.26 (-0.07)
Asterias Biotherapeutics Announces Change to Presentation Time at Needham Healthcare Conference
PR Newswire - Thu Apr 09, 12:56PM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger, President and Chief Executive Officer of Asterias, will present at the 14th Annual Needham Healthcare Conference in New York City on April 15, 2015 at 3:40 PM ET/12:40 PM PT. Mr. Lichtinger's presentation was originally scheduled for 5:00 PM ET/2:00 PM PT.
AST: 14.77 (+0.66)
Asterias Biotherapeutics to Present at Needham Healthcare Conference
PR Newswire - Mon Apr 06, 6:00AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger, President and Chief Executive Officer of Asterias, will present at the 14th Annual Needham Healthcare Conference in New York City on April 15, 2015 at 5:00 PM ET/2:00 PM PT.
AST: 14.77 (+0.66)
Asterias Biotherapeutics to Present at Regen Med Investor Day 2015
PR Newswire - Wed Mar 18, 6:00AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger, President and Chief Executive Officer of Asterias, will present at the Regen Med Investor Day 2015 Conference at the Metropolitan Club in New York City on March 25, 2015 at 5:05 PM ET/2:05 PM PT.
AST: 14.77 (+0.66)
Asterias Biotherapeutics' (AST) CEO Pedro Lichtinger on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 10, 6:07PM CDT
AST: 14.77 (+0.66)
Asterias Biotherapeutics beats by $0.02
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 3:06PM CDT
AST: 14.77 (+0.66)
Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
PR Newswire - Tue Mar 10, 3:01PM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today reported financial results and progress for the quarter and year ended December 31, 2014, as well as, recent corporate developments.
AST: 14.77 (+0.66)
Asterias breaks out in early trading
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 11:30AM CDT
AST: 14.77 (+0.66)
Next Week In Biotech: Kythera Ad Comm, Roth Conference, Zogenix Earnings
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 9.26 (+0.05), OMED: 26.16 (+0.29), BIOA: 10.44 (-0.24), SUPN: 13.76 (-0.18), CTIC: 1.96 (+0.01), ALXA: 1.94 (-0.06), DSCI: 8.09 (-0.31), ANTH: 5.20 (+0.31), CYTX: 0.99 (+0.01), KYTH: 50.44 (-0.54), ANAC: 64.49 (-2.10), ATHX: 1.29 (-0.03), CRMD: 8.61 (-0.22), ACRX: 4.58 (-0.16), TROV: 8.80 (-0.13), ZGNX: 1.54 (-0.11), PETX: 15.86 (-0.43), RPRX: 8.43 (-0.06), IMUC: 0.53 (-0.01), PGNX: 6.03 (-0.38), SNTA: 2.69 (-0.28), BLCM: 27.88 (-0.46), TXMD: 7.12 (-0.12), OGXI: 2.19 (+0.04), AST: 14.77 (+0.66), PLX: 2.23 (+0.01), ATRS: 2.72 (-0.04)
Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015
PR Newswire - Mon Mar 02, 6:00AM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it will release fourth quarter and full year 2014 financial and operating results on Tuesday, March 10, 2015 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Tuesday, March 10, 2015 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results and recent corporate developments.
AST: 14.77 (+0.66)
What's New in the Biotechnology Sector: Special Research on Vical,Asterias, Bacterin, Hemispherx BioPharma, and IGI Laboratories
PR Newswire - Thu Feb 19, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
VICL: 1.00 (-0.03), HEB: 0.24 (-0.01), AST: 14.77 (+0.66), IG: 8.94 (-0.26)
InsiderInsights.com Daily Round Up 2/11/15: GRUB, FSC, RENT, SXC
InsiderInsights - at Seeking Alpha - Thu Feb 12, 11:02AM CST
GRA: 97.07 (+0.11), GRUB: 46.00 (-0.25), SXC: 17.43 (-0.09), RENT: 50.18 (-0.12), ASPX: 100.88 (-0.01), BH: 396.61 (+1.13), NOW: 76.09 (-0.79), FSC: 7.15 (unch), NWL: 39.54 (-0.08), AST: 14.77 (+0.66), AVNU: 11.94 (+0.29), WDR: 50.21 (-0.03), DATA: 102.40 (+0.20), CRM: 67.83 (-0.64)
Asterias Biotherapeutics Completes Public Offering and Private Placement of Common Stock
PR Newswire - Tue Feb 10, 2:00PM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company"
, a leading biotechnology company in the emerging field of regenerative medicine, announced today that it has completed the previously announced underwritten public offering and concurrent private placement of its common stock.
BTX: 5.72 (-0.16), AST: 14.77 (+0.66)
Asterias Biotherapeutics begins public offering of common shares
M2 - Fri Feb 06, 5:24AM CST
Biotechnology company Asterias Biotherapeutics (NYSE MKT:AST) reported on Thursday that it has launched an underwritten public offering of its common stock pursuant to its existing effective shelf registration statement filed with the Securities and Exchange Commission.
AST: 14.77 (+0.66)
Asterias Biotherapeutics Prices Public Offering of Common Stock
PR Newswire - Thu Feb 05, 9:37AM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company", a leading biotechnology company in the emerging field of regenerative medicine, today announced today that it has priced an underwritten public offering of its common stock at a price of $3.90 per share. Concurrently, the Company entered into a private placement for the sale of common stock at the same price as the underwritten public offering.
BTX: 5.72 (-0.16), AST: 14.77 (+0.66)
Asterias Biotherapeutics Announces Public Offering of Common Stock
PR Newswire - Wed Feb 04, 3:33PM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company", a leading biotechnology company in the emerging field of regenerative medicine, today announced that it has commenced an underwritten public offering of its common stock. MLV & Co. LLC is acting as the Sole Book-Running Manager for the offering.
BTX: 5.72 (-0.16), AST: 14.77 (+0.66)
BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer Therapy
Business Wire - Mon Jan 26, 7:01AM CST
BioTime, Inc. (NYSE MKT: BTX) announced today the issuance of 14 new patents covering a wide range of the core technologies of BioTime and its subsidiaries Asterias Biotherapeutics, Inc. (NYSE MKT: AST), OrthoCyte Corporation, ES Cell International Pte Ltd, OncoCyte Corporation, and ReCyte Therapeutics, Inc. The new patents issued over Q3 and Q4 of 2014 add to the BioTime family of companies' patent estate of over 600 patents and patent applications pending worldwide, which is the largest known patent estate in the field of pluripotent stem cell technology for human therapeutic application, an emerging field known as "regenerative medicine."
BTX: 5.72 (-0.16), AST: 14.77 (+0.66)
What's New in the Pharma Sector: Free Research on Asterias, Dicerna,OncoMed, Heron, and Providence Service Corporation
PR Newswire - Thu Apr 23, 7:20AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PRSC: 49.35 (+0.02), HRTX: 14.18 (-0.06), DRNA: 24.18 (-0.25), OMED: 26.16 (+0.29), AST: 14.77 (+0.66)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 11:47AM CDT
RNO: 2.09 (+0.13), ECHO: 32.68 (-1.14), LJPC: 22.95 (-1.39), CEA: 40.74 (-2.76), NVGN: 6.54 (-0.01), NHLD: 3.78 (-0.18), VLTC: 11.54 (+0.50), GEVO: 2.72 (-0.10), BIOD: 1.14 (-0.13), PRTO: 12.30 (+0.01), TTS: 14.01 (-0.17), ENZN: 1.72 (+0.18), AST: 14.77 (+0.66), VGGL: 2.55 (-0.10), GLF: 13.58 (-0.05), NVTA: 13.23 (+0.41), FTK: 14.06 (-0.43), PGN: 1.69 (unch), UCTT: 6.26 (+0.60), SANM: 20.81 (-0.03)
Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting
PR Newswire - Tue Apr 21, 6:00AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that the abstract describing long-term follow-up of patients with acute myelogenous leukemia (AML) from the Phase 2 clinical trial of the Company's autologous telomerase-based dendritic cell cancer vaccine, AST-VAC1, has been selected for an oral presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago, Illinois May 29 - June 2, 2015.
AST: 14.77 (+0.66)
AusNet Services Selects Silver Spring Networks for Advanced Metering Roll-Out
Business Wire - Thu Apr 16, 7:30AM CDT
Silver Spring Networks (NYSE:SSNI) today announced its selection by AusNet Services (ASX:AST), the state of Victoria's largest diversified energy network business, to support its roll-out of the Victorian government's mandated Advanced Metering Infrastructure (AMI) program. Silver Spring will deploy and support the initial operations of a multi-application, IPv6 network canopy as an infill solution within AusNet Services' territory across Eastern Victoria. The Silver Spring solution will complement AusNet Services' existing core technology systems.
AST: 14.77 (+0.66), SSNI: 10.26 (-0.07)
Asterias Biotherapeutics Announces Change to Presentation Time at Needham Healthcare Conference
PR Newswire - Thu Apr 09, 12:56PM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger, President and Chief Executive Officer of Asterias, will present at the 14th Annual Needham Healthcare Conference in New York City on April 15, 2015 at 3:40 PM ET/12:40 PM PT. Mr. Lichtinger's presentation was originally scheduled for 5:00 PM ET/2:00 PM PT.
AST: 14.77 (+0.66)
Asterias Biotherapeutics to Present at Needham Healthcare Conference
PR Newswire - Mon Apr 06, 6:00AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger, President and Chief Executive Officer of Asterias, will present at the 14th Annual Needham Healthcare Conference in New York City on April 15, 2015 at 5:00 PM ET/2:00 PM PT.
AST: 14.77 (+0.66)
Asterias Biotherapeutics to Present at Regen Med Investor Day 2015
PR Newswire - Wed Mar 18, 6:00AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger, President and Chief Executive Officer of Asterias, will present at the Regen Med Investor Day 2015 Conference at the Metropolitan Club in New York City on March 25, 2015 at 5:05 PM ET/2:05 PM PT.
AST: 14.77 (+0.66)
Asterias Biotherapeutics' (AST) CEO Pedro Lichtinger on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 10, 6:07PM CDT
AST: 14.77 (+0.66)
Asterias Biotherapeutics beats by $0.02
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 3:06PM CDT
AST: 14.77 (+0.66)
Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
PR Newswire - Tue Mar 10, 3:01PM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today reported financial results and progress for the quarter and year ended December 31, 2014, as well as, recent corporate developments.
AST: 14.77 (+0.66)
Asterias breaks out in early trading
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 11:30AM CDT
AST: 14.77 (+0.66)
Next Week In Biotech: Kythera Ad Comm, Roth Conference, Zogenix Earnings
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 9.26 (+0.05), OMED: 26.16 (+0.29), BIOA: 10.44 (-0.24), SUPN: 13.76 (-0.18), CTIC: 1.96 (+0.01), ALXA: 1.94 (-0.06), DSCI: 8.09 (-0.31), ANTH: 5.20 (+0.31), CYTX: 0.99 (+0.01), KYTH: 50.44 (-0.54), ANAC: 64.49 (-2.10), ATHX: 1.29 (-0.03), CRMD: 8.61 (-0.22), ACRX: 4.58 (-0.16), TROV: 8.80 (-0.13), ZGNX: 1.54 (-0.11), PETX: 15.86 (-0.43), RPRX: 8.43 (-0.06), IMUC: 0.53 (-0.01), PGNX: 6.03 (-0.38), SNTA: 2.69 (-0.28), BLCM: 27.88 (-0.46), TXMD: 7.12 (-0.12), OGXI: 2.19 (+0.04), AST: 14.77 (+0.66), PLX: 2.23 (+0.01), ATRS: 2.72 (-0.04)
Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015
PR Newswire - Mon Mar 02, 6:00AM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it will release fourth quarter and full year 2014 financial and operating results on Tuesday, March 10, 2015 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Tuesday, March 10, 2015 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results and recent corporate developments.
AST: 14.77 (+0.66)
What's New in the Biotechnology Sector: Special Research on Vical,Asterias, Bacterin, Hemispherx BioPharma, and IGI Laboratories
PR Newswire - Thu Feb 19, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
VICL: 1.00 (-0.03), HEB: 0.24 (-0.01), AST: 14.77 (+0.66), IG: 8.94 (-0.26)
InsiderInsights.com Daily Round Up 2/11/15: GRUB, FSC, RENT, SXC
InsiderInsights - at Seeking Alpha - Thu Feb 12, 11:02AM CST
GRA: 97.07 (+0.11), GRUB: 46.00 (-0.25), SXC: 17.43 (-0.09), RENT: 50.18 (-0.12), ASPX: 100.88 (-0.01), BH: 396.61 (+1.13), NOW: 76.09 (-0.79), FSC: 7.15 (unch), NWL: 39.54 (-0.08), AST: 14.77 (+0.66), AVNU: 11.94 (+0.29), WDR: 50.21 (-0.03), DATA: 102.40 (+0.20), CRM: 67.83 (-0.64)
Asterias Biotherapeutics Completes Public Offering and Private Placement of Common Stock
PR Newswire - Tue Feb 10, 2:00PM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company"
, a leading biotechnology company in the emerging field of regenerative medicine, announced today that it has completed the previously announced underwritten public offering and concurrent private placement of its common stock. BTX: 5.72 (-0.16), AST: 14.77 (+0.66)
Asterias Biotherapeutics begins public offering of common shares
M2 - Fri Feb 06, 5:24AM CST
Biotechnology company Asterias Biotherapeutics (NYSE MKT:AST) reported on Thursday that it has launched an underwritten public offering of its common stock pursuant to its existing effective shelf registration statement filed with the Securities and Exchange Commission.
AST: 14.77 (+0.66)
Asterias Biotherapeutics Prices Public Offering of Common Stock
PR Newswire - Thu Feb 05, 9:37AM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company"
, a leading biotechnology company in the emerging field of regenerative medicine, today announced today that it has priced an underwritten public offering of its common stock at a price of $3.90 per share. Concurrently, the Company entered into a private placement for the sale of common stock at the same price as the underwritten public offering. BTX: 5.72 (-0.16), AST: 14.77 (+0.66)
Asterias Biotherapeutics Announces Public Offering of Common Stock
PR Newswire - Wed Feb 04, 3:33PM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company"
, a leading biotechnology company in the emerging field of regenerative medicine, today announced that it has commenced an underwritten public offering of its common stock. MLV & Co. LLC is acting as the Sole Book-Running Manager for the offering. BTX: 5.72 (-0.16), AST: 14.77 (+0.66)
BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer Therapy
Business Wire - Mon Jan 26, 7:01AM CST
BioTime, Inc. (NYSE MKT: BTX) announced today the issuance of 14 new patents covering a wide range of the core technologies of BioTime and its subsidiaries Asterias Biotherapeutics, Inc. (NYSE MKT: AST), OrthoCyte Corporation, ES Cell International Pte Ltd, OncoCyte Corporation, and ReCyte Therapeutics, Inc. The new patents issued over Q3 and Q4 of 2014 add to the BioTime family of companies' patent estate of over 600 patents and patent applications pending worldwide, which is the largest known patent estate in the field of pluripotent stem cell technology for human therapeutic application, an emerging field known as "regenerative medicine."
BTX: 5.72 (-0.16), AST: 14.77 (+0.66)
